# Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

> **NCT01210443** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 2 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Sitaxentan

## Key facts

- **NCT ID:** NCT01210443
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.
- **Last updated:** 2011-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210443, "Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01210443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*